With ≥15% weight loss from AOMs like semaglutide and tirzepatide, nutritional guidance is critical. Almandoz et al. (2024) provide practical recommendations on protein intake, micronutrient monitoring, and individualized care—helping clinicians…
GLP-1 and GIP/GLP-1 therapies reduce calorie intake—but Christensen et al. (2024) show we know little about diet quality, protein intake, or micronutrient risks. With use rising, tailored nutritional support is…
Even with high caloric intake, people with overweight or obesity often face silent micronutrient deficiencies—impacting metabolism, cognition, and long-term weight outcomes. This review by Astrup & Bügel (2017) underscores the…